Clinical trials: HIV-infected
Discordant Immunological Response in HIV Infected Subjects
Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response
Phase I/IIClinical trial, proof of concept, double blind, and placebo-controlled, randomized 2:1 (MSCs: placebo), total sample size is 15 subjects
- Trial name
- NCT02290041
- Testing
- Infusion of MSC
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
PNC Vaccine, HIV-infected Pregnant Women
Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women
The purpose of this study was to determine the safety, reactogenicity, immunogenicity, transplacental antibody transfer and interference with infant responses to childhood vaccination of maternal vaccination with pneumococcal…
- Trial name
- NCT02717494
- Testing
- PPV-23, PCV-10, NaCl
- Where
- 8 sites in Brazil
- Volunteers
- 347 people
- Sponsor
- Westat
HIV Infected Individuals
The Influence of Psychological Interventions Upon Disease Progression in HIV-infected Patients Receiving no Medication
This study examines the hypothesis that psychological interventions have beneficial effects on quality of life including psychological well-being and disease progression in early HIV patients recieving no medication.
- Trial name
- NCT00180700
- Testing
- Hypnosis
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- Imperial College London
HIV-1 Infected Adults With Chronic HIV-1 Infection
Enhancement by Poly-ICLC During HIV-1 Infection
This study involves researching new approaches to treating HIV infection. Currently, HIV infection is treated with combinations of drugs called antiretrovirals.
- Trial name
- Poly-ICLC (NCT02071095)
- Testing
- Arm A: Poly-ICLC, Arm B: Normal Saline
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nina Bhardwaj
HIV Infected Patients With Cancer Treated by ICPi
ANRS CO24 OncoVIHAC (Onco VIH Anti Checkpoint)
A Multicenter, Observational, National Cohort for HIV Infected Patients with a Cancer treated by Immune-Checkpoint Inhibitors (ICPi) for less than one month or to be treated with an ICPi such as anti-PD-1 or anti-PDL-1 or…
- Trial name
- OncoVIHAC (NCT03354936)
- Testing
- Blood sample
- Where
- 56 sites in France
- Volunteers
- 50 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-infected Patients
Effect of Aspirin on Abacavir-induced Platelet Reactivity in HIV-infected Patients
The specific research questions addressed in the present study are: to investigate the impact of treatment with low-dose aspirin in HIV-1-infected patients treated with ABC and test it would result in decreased in vivo platelet…
- Trial name
- ABC-ASA (NCT03316534)
- Testing
- Aspirin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera di Perugia
Hazardous Drinking, Binge Drinking
A Stage 2 Cognitive-behavioral Trial: Reduce Alcohol First in Kenya Intervention
This study will determine whether a group cognitive-behavioral therapy intervention that demonstrates preliminary evidence of reducing alcohol use among HIV-infected outpatients in western Kenya is effective when compared against…
- Conditions
- Hazardous Drinking, Binge Drinking, HIV-infected
- Trial name
- RAFIKI (NCT01503255)
- Testing
- cognitive behavioral group therapy, health education group
- Where
- Kenya
- Volunteers
- 614 people
- Sponsor
- Brown University
HIV-infected Patients
Values of the Immune Activation Markers CD38 and HLA-DR and the Ratio CD4/CD8 According to the Delay of Combined AntiRetroviral Therapy (c-ART) Initiation in Primary HIV-infected Patients (PRIMIMMUNO)
The objective was to identify factors associated with the normalization of the CD4/CD8 ratio (>=1) in patients with a history of primary HIV infection (PHI) and long-term combined antiretroviral therapy (cART).
- Trial name
- PRIMIMMUNO (NCT02827227)
- Testing
- lymphocytes immunophenotyping
- Where
- France
- Volunteers
- 99 people
- Sponsor
- Hospices Civils de Lyon
Treatment Failure of Second-line ART in Asian HIV-infected Children
Second-line Therapy
This study will help identify which ARV candidates should be prioritized for pediatric use in resource-limited settings
- Trial name
- TASER-P (NCT01788891)
- Where
- 8 sites in Indonesia, Malaysia and 2 more
- Volunteers
- 300 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
T Cell Response to Asthma in HIV-infected Patients Before and After Starting Treatment
Children With HIV and Asthma (CHIVAS)
To explore allergen-specific effector and regulatory T cell response in HIV-infected children before and after HAART initiation
- Trial name
- NCT01644370
- Testing
- HAART
- Where
- 2 sites in Thailand
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV-HCV Co-infected Patients
Analysis of Host Genetic Factors in the Occurrence of Anemia and on the Virological Response to a Peg-interferon/Ribavirin Therapy in HIV-HCV Co-infected Patients
The treatment of HCV (hepatitis C virus) infection has made significant progress over the past decade with the therapy combining pegylated interferon (Peg-IFN) to ribavirin (RBV).
- Trial name
- NCT01964742
- Testing
- blood samples
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
HIV Infected Women, Healthy Women Volunteers
Study of Immunity at the Genital Mucosa of HIV-1 Infected and Healthy Women
Current knowledge on mucosa, especially genitals in women, however, remain inadequate, especially regarding defense mechanisms and possibilities for a vaccine to induce an active immune response at mucosal front door of the most…
- Trial name
- MUCOVAC (NCT01715103)
- Testing
- vaginal swabs by washing and cytobrush
- Where
- 2 sites in France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-infected Children
Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)
To compare the safety and efficacy of low-dose versus standard dose lopinavir/ritonavir containing HAART regimen in virological suppress, HIV RNA viral load < 50 copies/ml at 48 week
- Trial name
- NCT01307124
- Testing
- kaletra
- Where
- 10 sites in Thailand
- Volunteers
- 199 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Antiretroviral Therapy in HIV-1 Infected Children
KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)
The trial will evaluate the pharmacokinetics, safety, efficacy and acceptability of twice- and once-daily dosing of lopinavir/ritonavir tablets (Kaletra) dosed by weight in HIV-1 infected children who are currently taking…
- Trial name
- KONCERT (NCT01196195)
- Testing
- Kaletra dosed once daily, kaletra dosed twice daily
- Where
- 17 sites in Germany, Ireland and 3 more
- Volunteers
- 173 people
- Sponsor
- PENTA Foundation
HIV Infected
Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women
Data suggests that women taking drugs to treat human immunodeficiency virus (HIV) have higher amounts of drugs in their body compared with men taking the same dose of anti-HIV drugs.
- Trial name
- NCT01394133
- Testing
- Tenofovir, Emtricitabine, Atazanavir, Ritonavir
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
HIV-1 Infected Patients, Fold-change Resistance
GePheRal: Clinical Validation of the Genotypic Diagnosis of Hiv-1 Resistance to Raltegravir by Parallel Analysis of the Genotype and Phenotype Profiles of Resistance
The purpose of this study is to correlate the different patterns of resistance mutations observed in vivo in patients failing RAL treatment with the fold-change resistance determined by the phenotypic assay.
- Conditions
- HIV-1 Infected Patients, Fold-change Resistance, Resistance Mutations
- Trial name
- NCT01381328
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Università Vita-Salute San Raffaele
Non HIV Infected Pregnant Women
IPT of Malaria With SP in Different Zones of Drug Resistance in Rwanda
The present study will address the question whether the use of IPT using SP in pregnancy is efficacious in Rwanda, where it is going to be used for the first time, in areas with high levels of SP resistance.
- Trial name
- NCT00372632
- Testing
- Sulfadoxine-Pyrimethamine
- Where
- Rwanda
- Volunteers
- 1,717 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Chronic Hepatitis C Infection in HIV Infected Persons, HIV Infections
HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy
Objectives: Primary To evaluate the safety, tolerability, and efficacy of Peginterferon a-2a plus Ribavirin for the treatment of chronic hepatitis C (CHC) infection in persons co-infected with human immunodeficiency virus (HIV)…
- Trial name
- NCT00215839
- Testing
- Peginterferon a-2a plus Ribavirin
- Where
- United States
- Sponsor
- Hepatitis Resource Network
Chronic Hepatitis C Infection in HIV-Infected Persons, HIV Infections
PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon
Objectives: Primary To compare the sustained virologic response (SVR) of PEGIntron plus ribavirin among patients receiving 48 weeks versus 72 weeks of therapy (defined as undetectable HCV RNA level 24 weeks after discontinuing…
- Trial name
- NCT00215891
- Testing
- PEG-Interferon a-2b + Ribavirin
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Hepatitis Resource Network